Search...
XJZY: The company's dexamethasone acetate tablets have passed the consistency evaluation of generic drugs
On August 22, XJZY announced that the company recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration regarding Dexamethasone Acetate Tablets. The company's Dexamethasone Acetate Tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Dexamethasone Acetate Tablets are a type of adrenal corticosteroid, mainly used for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, dermatitis and other allergic diseases, ulcerative colitis, acute leukemia, malignant lymphoma, etc
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments